Emerson has purchased Fluxa, a provider of life sciences software.
Fluxa accelerates the speed to market for therapies by helping drug development and manufacturing firms collaborate.
“The life sciences industry has grown rapidly and speed to market has become increasingly important since the emergence of COVID-19,” said Mark Bulanda, executive president of Emerson. “Emerson’s automation solutions and market leadership, combined with Fluxa’s software, automate technology transfer in one step, giving biopharmaceutical companies unprecedented agility to get therapies safely to patients during this critical time.”